Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewGPi 688 is an allosteric glycogen phosphorylase inhibitor; acts at the indole site of glycogen phosphorylase. Inhibits glucagon-mediated hyperglycemia in vivo in the rat.
Sold with the permission of AstraZeneca UK Ltd.
M. Wt | 419.88 |
Formula | C19H18ClN3O4S |
Storage | Store at +4°C |
Purity | ≥99% (HPLC) |
CAS Number | 918902-32-6 |
PubChem ID | 10477191 |
InChI Key | UICNBXVDHCBKCE-PUODRLBUSA-N |
Smiles | OC[C@H](O)CN(C1=CC=CC=C1CC2NC(C3=CC4=C(SC(Cl)=C4)N3)=O)C2=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Freeman et al (2006) Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme. Br.J.Pharmacol. 149 775 PMID: 17016495
Poucher et al (2007) An assessment of the in vivo efficacy of the glycogen phosphorylase inhibitor GPi688 in rat models of hyperglycaemia. Br.J.Pharmacol. 152 1239 PMID: 17934512
Keywords: GPi 688, GPi 688 supplier, GPi688, glycogen, phosphorylase, inhibitors, hyperglycaemia, hyperglycemia, inhibits, astrazeneca, Phosphorylases, 3967, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for GPi 688.
There are currently no reviews for this product. Be the first to review GPi 688 and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image